Your about to leave the site and are being redirected to another site. Would you like to leave this site?

Image-1

2 INDICATIONS 

APPROVED

Image-1

Register for/view a webcast about BAVENCIO.

NOW APPROVED for the treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) with disease progression during or following platinum-containing chemotherapy, or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy

The FIRST AND ONLY FDA-approved anti-PD-L1 immunotherapy for adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (mMCC)1

indications

BAVENCIO (avelumab) is indicated for the treatment of:

  • Adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC)
  • Patients with locally advanced or metastatic urothelial carcinoma (UC) who have disease progression during or following platinum-containing chemotherapy, or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy 

These indications are approved under accelerated approval based on tumor response and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in confirmatory trials.

Visit CoverOne.com to learn about patient access and reimbursement support for BAVENCIO—or call 844-8COVER1
(844-826-8371).